Loading...
XNAS
TGTX
Market cap5.63bUSD
May 20, Last price  
35.47USD
1D
1.40%
1Q
14.38%
Jan 2017
662.80%
Name

TG Therapeutics Inc

Chart & Performance

D1W1MN
P/E
240.82
P/S
17.12
EPS
0.15
Div Yield, %
—
Shrs. gr., 5y
12.65%
Rev. gr., 5y
364.59%
Revenues
329m
+40.80%
000000019,048152,381152,381152,381152,381152,381152,000152,000152,0006,689,0002,785,000233,662,000329,004,000
Net income
23m
+84.52%
-19,140,997-9,695,123-12,032,252-4,268,858-2,793,285623,645-853,074-18,072,719-20,478,210-55,781,277-62,948,646-78,252,894-118,476,012-173,482,000-179,347,000-285,878,000-355,552,000-203,831,00012,672,00023,383,000
CFO
-41m
L+28.98%
-6,244,942-7,750,738-10,229,711-4,444,009-1,049,799-1,970,113-86,577-5,187,964-10,824,231-35,059,919-44,690,272-61,591,330-93,763,562-128,925,000-132,806,000-214,507,000-295,634,000-176,170,000-31,413,000-40,517,000
Earnings
Aug 04, 2025

Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
URL
https://www.tgtherapeutics.com/
IPO date
Dec 14, 1995
Employees
244
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
329,004
40.80%
233,662
8,290.02%
2,785
-58.36%
Cost of revenue
287,075
213,452
259,670
Unusual Expense (Income)
NOPBT
41,929
20,210
(256,885)
NOPBT Margin
12.74%
8.65%
Operating Taxes
2,211
390
5,496
Tax Rate
5.27%
1.93%
NOPAT
39,718
19,820
(262,381)
Net income
23,383
84.52%
12,672
-106.22%
(203,831)
-42.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
(8,760)
46,296
584
BB yield
0.18%
-1.83%
-0.04%
Debt
Debt current
1,157
2,892
1,581
Long-term debt
261,852
120,026
93,404
Deferred revenue
6,016
305
Other long-term liabilities
12,085
71,440
Net debt
(48,799)
(94,590)
(91,501)
Cash flow
Cash from operating activities
(40,517)
(31,413)
(176,170)
CAPEX
(14)
Cash from investing activities
(1,036)
(50,651)
(20,013)
Cash from financing activities
128,527
72,705
(391)
FCF
(75,518)
(27,110)
(262,135)
Balance
Cash
311,000
217,508
174,082
Long term investments
808
12,404
Excess cash
295,358
205,825
186,347
Stockholders' equity
(1,529,038)
(1,514,210)
(1,526,887)
Invested Capital
2,017,206
1,792,969
154,659
ROIC
2.08%
2.04%
ROCE
8.59%
7.25%
EV
Common stock shares outstanding
160,336
148,508
135,411
Price
30.10
76.23%
17.08
44.38%
11.83
-37.74%
Market cap
4,826,115
90.26%
2,536,525
58.34%
1,601,915
-36.24%
EV
4,777,316
2,441,935
1,510,414
EBITDA
41,997
20,633
(256,370)
EV/EBITDA
113.75
118.35
Interest
24,028
12,615
10,191
Interest/NOPBT
57.31%
62.42%